Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Clinical Trial Data

Every clinical trial data filing by a US-listed company that our alert engine sent, newest first.

4:10 PM ET 8-K
Clinical Trial Data Korro Bio, Inc. KRRO

Korro Bio Clinical Trial Data

Korro Bio announced the dosing of the first cohort of participants in its ANCHOR Phase 1/2 clinical trial for KRRO-121, an RNA-editing oligonucleotide targeting hyperammonemia in patients with urea cycle disorders (UCD). The trial is currently enrolling healthy volunteers in Australia for safety and PK evaluation, with dosing in UCD patients expected to begin in the first half of 2027.

“Dosing the first cohort in ANCHOR is a step towards gaining evidence on safety first and then activity. Providing the potential for peace of mind for patients with a UCD, irrespective of their mutational background, is something we hope to demonstrate through this trial.”

Ram Aiyar, PhD, Chief Executive Officer and President of Korro
8:30 AM ET 8-K
Clinical Trial Data Coya Therapeutics, Inc. COYA

Coya Therapeutics Clinical Trial Data

Coya Therapeutics announced it has achieved full enrollment of 120 patients in its Phase 2/3 ALSTARS trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The company expects to release topline data from the double-blind treatment phase in early Q2 2027.

8:01 AM ET 8-K
Clinical Trial Data Vaxcyte, Inc. PCVX

Vaxcyte Clinical Trial Data

Vaxcyte announced positive topline results from its OPUS-1 pivotal Phase 3 trial of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate for adults. The trial met all prespecified primary immunogenicity and safety endpoints, demonstrating noninferiority to Prevnar 20 and Capvaxive. These results will support a planned Biologics License Application (BLA) submission to the FDA in the first half of 2028.

Earnings call
Oct 5, 2026, 8:00 AM ET
4:15 PM ET 8-K
Clinical Trial Data BioAge Labs, Inc. BIOA

BioAge Labs Clinical Trial Data

BioAge Labs announced the first participant has been dosed in its QUELL-DME Phase 2 clinical trial evaluating BGE-102, an oral NLRP3 inhibitor, for the treatment of diabetic macular edema. The 180-participant trial will evaluate the drug as both a monotherapy and in combination with anti-VEGF therapy, with topline results expected in the second half of 2027.

8:19 AM ET 8-K
Clinical Trial Data Century Therapeutics, Inc. IPSC

Century Therapeutics Clinical Trial Data

Century Therapeutics presented updated nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at the EASD 2026 meeting. The data demonstrated sustained glycemic control in diabetic mouse models for over eleven months and confirmed manufacturing consistency across five clinical-scale batches. The company remains on track to submit an IND for CNTY-813 in Q4 2026, with initial clinical data expected in the second half of 2027.

Counterparty
European Association for the Study of Diabetes (EASD)
9:16 AM ET 8-K
Clinical Trial Data Gain Therapeutics, Inc. GANX

Gain Therapeutics Clinical Trial Data

Gain Therapeutics presented 12-month open-label extension data from its Phase 1b study of rexaceract, showing stabilization of MDS-UPDRS motor scores in Parkinson’s disease patients. The data suggests disease-modifying potential as patients showed no clinically meaningful progression of motor symptoms over the one-year period. The company plans to submit a Phase 2 protocol to the FDA and initiate a Phase 2 trial in Q1 2027.

Term
12 months
8:11 AM ET 8-K
Clinical Trial Data Azitra, Inc. AZTR

Azitra Clinical Trial Data

Azitra, Inc. has completed Cohort 1 of its Phase 1/2 clinical trial for ATR-04, a live biotherapeutic candidate for treating skin rash associated with EGFR inhibitors. Following a safety review committee clearance, the company is proceeding to enroll approximately 24 patients in Cohort 2 to further evaluate safety, tolerability, and preliminary efficacy.

8:02 AM ET 8-K
Clinical Trial Data Evommune, Inc. EVMN

Evommune Clinical Trial Data

Evommune presented Phase 2a proof-of-concept data for EVO301 in patients with moderate-to-severe atopic dermatitis, showing a 55% mean reduction in EASI scores at Week 12 compared to 22% for placebo. The trial validated IL-18 inhibition as a novel therapeutic approach with a favorable safety profile, and the company plans to initiate a Phase 2b dose-ranging trial in mid-2027.

Counterparty
European Academy of Dermatology and Venereology (EADV)
7:59 AM ET 8-K
Clinical Trial Data Nektar Therapeutics NKTR

Nektar Therapeutics Clinical Trial Data

Nektar Therapeutics announced long-term Phase 2b data for rezpegaldesleukin in patients with alopecia areata (REZOLVE-AA) and atopic dermatitis (REZOLVE-AD) at the EADV Congress 2026. The data demonstrated sustained hair regrowth and deepening of response even six months after treatment cessation, suggesting a differentiated regulatory T cell (Treg) mechanism compared to existing systemic therapies.

Earnings call
Oct 1, 2026, 3:00 PM ET
7:39 AM ET 8-K
Clinical Trial Data Monte Rosa Therapeutics, Inc. GLUE

Monte Rosa Therapeutics Clinical Trial Data

Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, a NEK7-directed molecular glue degrader for inflammatory diseases. The GFORCE-1 study in 108 subjects showed 80-90% NEK7 degradation and normalization of key ASCVD pathogenic drivers with a favorable safety profile, supporting the planned initiation of multiple Phase 2 studies in coronary artery disease, gout, and hidradenitis suppurativa.

Earnings call
Oct 1, 2026, 8:00 AM ET
9:20 AM ET 8-K
Clinical Trial Data Q32 Bio Inc. QTTB

Q32 Bio Clinical Trial Data

Q32 Bio presented additional 36-week results and initial 16-week off-drug findings from its SIGNAL-AA Phase 2a trial of bempikibart in patients with severe alopecia areata. The data showed clinically meaningful efficacy, including a 35.3% mean reduction in SALT scores, and supported the drug's advancement into a registration-directed program in the first half of 2027.

“Bempikibart’s robust efficacy data and durability observed across the 36-week treatment period and 16-week off-drug period in both JAK inhibitor-experienced and JAK inhibitor-naïve patients, changes on biomarkers supportive of its bifunctional mechanism, and its favorable safety and tolerability profile support its continued development in a registration-directed program in patients with severe or very severe alopecia areata as well as in expanded alopecia areata populations and other autoimmune and inflammatory indications.”

Jodie Morrison, Chief Executive Officer of Q32 Bio
8:52 AM ET 8-K
Clinical Trial Data Silexion Therapeutics Corp SLXN

Silexion Therapeutics Clinical Trial Data

Silexion Therapeutics has successfully dosed the first patient in its Phase 2/3 clinical trial of SIL204 for the treatment of locally advanced pancreatic cancer (LAPC). The trial evaluates SIL204 in combination with standard chemotherapy using a dual-route delivery strategy involving both intratumoral and subcutaneous administration. This milestone marks the transition of the company's lead RNAi program into active clinical execution across sites in Israel and Germany.

Counterparty
Tel Aviv Sourasky Medical Center
7:24 AM ET 8-K
Clinical Trial Data Rafael Holdings, Inc. RFL

Rafael Holdings Clinical Trial Data

Rafael Holdings announced topline results from its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo in 94 patients with Niemann-Pick Disease Type C. While the study did not achieve statistical significance on the primary endpoint in the overall population, a prespecified analysis of patients on background therapy (83% of the study) showed a statistically significant slowing of disease progression. The company remains on track to submit a New Drug Application (NDA) to the FDA in the fourth quarter of 2026.

Counterparty
Cyclo Therapeutics, LLC
Term
96 weeks
Earnings call
Sep 30, 2026, 8:30 AM ET
7:14 AM ET 8-K
Clinical Trial Data Jade Biosciences, Inc. JBIO

Jade Biosciences Clinical Trial Data

Jade Biosciences announced preclinical data for JADE301, an anti-interferon beta monoclonal antibody being developed for dermatomyositis. The data demonstrated high-affinity binding, potent inhibition of downstream signaling, and a differentiated pharmacokinetic profile supporting infrequent subcutaneous dosing. The company expects to initiate a Phase 1 clinical trial in healthy volunteers in Q4 2026, with interim data anticipated in the second half of 2027.

7:05 AM ET 8-K
Clinical Trial Data Connect Biopharma Holdings Ltd CNTB

Connect Biopharma Holdings Clinical Trial Data

Connect Biopharma announced positive topline results from its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation. The study met its primary endpoint, with rademikibart reducing the rate of treatment failure by 81% and eliminating hospital readmissions or emergency department visits for new exacerbations through Week 4. The company plans to engage with the FDA to align on a Phase 3 registrational development program.

Earnings call
Sep 30, 2026, 8:00 AM ET
5:20 PM ET 8-K
Clinical Trial Data Tectonic Therapeutic, Inc. TECX

Tectonic Therapeutic Clinical Trial Data

Tectonic Therapeutic announced favorable topline results from its Phase 1a clinical trial of TX2100, demonstrating that single ascending doses were generally safe and well-tolerated in healthy volunteers. The company also received FDA Fast Track designation and IND clearance to proceed with Phase 1b and Phase 2 trials in patients with Hereditary Hemorrhagic Telangiectasia (HHT).

4:46 PM ET 8-K
Clinical Trial Data Phathom Pharmaceuticals, Inc. PHAT

Phathom Pharmaceuticals Clinical Trial Data

Phathom Pharmaceuticals has initiated patient screening for pHalcon-NERD-302, a registrational Phase 3 study evaluating VOQUEZNA (vonoprazan) as an as-needed treatment for Non-Erosive Gastroesophageal Reflux Disease (NERD). The multicenter study aims to enroll approximately 500 adults across 80 U.S. sites, with topline results expected in the first quarter of 2028.

4:19 PM ET 8-K
Clinical Trial Data Apyx Medical Corp APYX

Apyx Medical Clinical Trial Data

Apyx Medical announced the publication of results from a prospective clinical study in Plastic and Reconstructive Surgery — Global Open evaluating its Renuvion helium plasma technology. The study demonstrated that Renuvion-treated tissue showed a 30% increase in elastin fiber density and a 34% reduction in inflammation, with 100% of participants reporting high satisfaction and visible improvements in skin quality.

4:11 PM ET 8-K
Clinical Trial Data Dyne Therapeutics, Inc. DYN

Dyne Therapeutics Clinical Trial Data

Dyne Therapeutics announced additional one-year clinical data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1), showing sustained functional improvement in myotonia, strength, and mobility. The data showed a 3.6-second relative improvement in hand myotonia at 6 months compared to placebo and divergence from a matched natural history cohort at 12 months. The company remains on track to report topline data from its registrational expansion cohort in Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in Q3 2027.

9:35 AM ET 8-K
Clinical Trial Data Oncolytics Biotech Inc ONCY

Oncolytics Biotech Clinical Trial Data

Oncolytics Biotech announced the publication of preclinical data in the Proceedings of the National Academy of Sciences demonstrating that its immunotherapy candidate, pelareorep, can transform immunologically inactive liver cancer tumors into active ones. The data showed pelareorep increased CD8+ T cell density and PD-L1 expression, potentially making challenging tumor types more susceptible to checkpoint inhibitors and other immunotherapies.

9:06 AM ET 8-K
Clinical Trial Data uniQure N.V. QURE

uniQure Clinical Trial Data

uniQure N.V. released a clinical program update for AMT-130 (ifezuntirgene inilparvovec), its gene therapy candidate for Huntington’s disease. The update includes long-term data from ongoing Phase I/II clinical trials and details regarding the enrollment of a fourth cohort. The company is also evaluating neurofilament light chain (NfL) in cerebrospinal fluid as a potential biomarker for disease severity.

8:45 AM ET 8-K
Clinical Trial Data Moleculin Biotech, Inc. MBRX

Moleculin Biotech Clinical Trial Data

Moleculin Biotech has completed and closed enrollment for Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia (R/R AML). The company enrolled 89 subjects and remains on track for a comprehensive data readout in the first quarter of 2027. The final Part A dataset is expected to provide efficacy insights across both 'fit' and 'unfit' patient populations, with an estimated 50/50 split between those previously treated with intensive chemotherapy versus venetoclax-based regimens.

7:36 AM ET 8-K
Clinical Trial Data Cartesian Therapeutics, Inc. RNAC

Cartesian Therapeutics Clinical Trial Data

Cartesian Therapeutics announced positive 12-month retreatment data from its Phase 2 trial of Descartes-08 in patients with myasthenia gravis (MG). The data showed that patients who were retreated after symptom recurrence experienced deep and durable responses, with a mean MG-ADL score reduction of 6.6 points at 12 months and no new safety signals. Topline data from the Phase 3 AURORA trial is expected in the first quarter of 2027.

7:27 AM ET 8-K
Clinical Trial Data Invivyd, Inc. IVVD

Invivyd Clinical Trial Data

Invivyd announced positive topline results from its LIBERTY Phase 3 study, which demonstrated that its COVID-19 monoclonal antibody candidate, VYD2311, had safety and tolerability superior to an mRNA-based vaccine. The company plans to use data from LIBERTY and the ongoing DECLARATION pivotal study to support a Biologics License Application (BLA) submission to the FDA via the Accelerated Approval Program.

Earnings call
Sep 29, 2026, 8:30 AM ET
7:00 AM ET 8-K
Clinical Trial Data Immix Biopharma, Inc. IMMX

Immix Biopharma Clinical Trial Data

Immix Biopharma announced positive interim results from its Phase 2 NEXICART-2 clinical trial of NXC-201 in relapsed/refractory AL Amyloidosis, showing an 89% complete response rate across 45 patients. The company noted that MRD-negativity predicts future complete responses, potentially increasing the rate to 98%, and plans a BLA submission for the therapy in mid-2027.

Earnings call
Sep 29, 2026, 8:00 AM ET
6:30 AM ET 8-K
Clinical Trial Data Alzamend Neuro, Inc. ALZN

Alzamend Neuro Clinical Trial Data

Alzamend Neuro presented Phase 1/2A clinical trial data for AL001, a novel organic lithium salt, at the ISMRT Conference. The study utilized 7T MRI imaging to evaluate brain pharmacokinetics, demonstrating that AL001 is designed for improved brain delivery with lower systemic exposure compared to standard inorganic lithium salts.

Counterparty
Massachusetts General Hospital
8:54 AM ET 8-K
Clinical Trial Data Kodiak Sciences Inc. KOD

Kodiak Sciences Clinical Trial Data

Kodiak Sciences announced that its Phase 3 DAYBREAK study in wet age-related macular degeneration (wAMD) met its primary endpoints for both Zenkuda and tabirafusp-ted. Both drugs demonstrated non-inferiority in vision gains compared to aflibercept, with Zenkuda showing 6-month durability in 54% of patients. The company plans to submit a multi-indication Biologics License Application (BLA) for Zenkuda in the fourth quarter of 2026.

8:47 AM ET 8-K
Clinical Trial Data Silexion Therapeutics Corp SLXN

Silexion Therapeutics Clinical Trial Data

Silexion Therapeutics announced positive preclinical translational research findings for its lead RNAi candidate, SIL204, demonstrating a mechanism for systemic uptake in KRAS-driven cancers. The study showed that SIL204 utilizes native serum lipids and lipoprotein pathways for cellular entry and gene silencing without the need for artificial nanoparticles, supporting its upcoming Phase 2/3 clinical program.

8:17 AM ET 8-K
Clinical Trial Data Transcode Therapeutics, Inc. RNAZ

Transcode Therapeutics Clinical Trial Data

TransCode Therapeutics announced updated Phase 1a clinical trial data for TTX-MC138, showing a 71.4% stable disease rate in patients with advanced solid tumors. The study met its primary safety endpoint with no dose-limiting toxicities reported, and three patients remained progression-free at the one-year mark. The company believes the durability of disease control warrants continued clinical evaluation of the RNA-based therapeutic candidate.

8:16 AM ET 8-K
Clinical Trial Data Adicet Bio, Inc. ACET

Adicet Bio Clinical Trial Data

Adicet Bio announced positive preliminary Phase 1 data for prula-cel in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing a 50% complete renal response rate and 54% DORIS remission at 12 months. The therapy was generally well tolerated with no Grade 3 or higher CRS and no ICANS, supporting potential outpatient administration. Based on these results, the company plans to initiate pivotal trial start-up activities in the fourth quarter of 2026.

Earnings call
Sep 28, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.